{"ticker": {"uuid": "de60177c-4106-45da-99f5-ff622386f9d2", "symbol": "NYKD", "name": "Nykode Therapeutics AS", "exchange": "OSL", "country": "NO", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "NYKD: Nykode Therapeutics Doses First Patient in Abili-T Phase II Randomized Trial evaluating Abi-suva in HPV16-Positive, PD-L1-Positive Recurrent or Metastatic Head and Neck Cancer Patients", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Finansavisen", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nykode Announces Updated Strategy to Increase Value for Patients and Shareholders, Prioritizing VB10.16 as the Lead Value Driver", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwJBVV95cUxQUjZYLWduVWl1eXlmX05RR2E2SFhwaGZ0V3JaMWt6Ri1Fb3BjeGxLRG1PQzVqMy1temE4c1ZwTmw4OE8yOFR2WHhJY2xndnF3TU5rYUNsSnU5SWtjcVhveVVMRl85dXNpcmN3NXRmTkZSYWMwNlJvZ05zNVNqWkhWcXJpbXpIb1RiSjRoNWVmVWIzT3RhOGYwbmRsQmVPelZ5M2t0cmxNLXA5Z05pME5pQ3NoRjlrTG54S1FQNXdrQXZwOVR1YWh5VUd0eXFIRklvbGstMGhHY3YyZi1PX2o0U1Mya2tZLUdnWEJpVUNJdFoyVmdJbGE2c3paRWpLTWl2MjdCeEFTSnRyZXZJVnFWUkw5MVN0X042SlJMZ0ZpUFp5VUpZZEdwMUR6UQ?oc=5", "source_name": "TradingView", "published_at": "2025-08-26T07:00:00+00:00", "published_display": "26 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NYKD Stock Price and Chart \u2014 OSL:NYKD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE5ocWJDaGt2Q3VkeHpXZWlzV2Nld0Z3R19YZmF2ZjdhWFRRUGxtM25RN3dMajVSNGtyMkNmUEt0dklwT0lrTnRBTmpjMFRhS19MY2Jid2xqUms?oc=5", "source_name": "TradingView", "published_at": "2024-12-12T08:00:00+00:00", "published_display": "12 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nykode Therapeutics (Formerly Vaccibody*)) Enters Into Multi-target License and Collaboration Agreement With Regeneron to Develop Innovative Vaccines Against Cancer and Infectious Diseases", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gJBVV95cUxPTEpPVFlPaTRIcm5nejBQSXdIMXVRNW5zcDhaZWh1TG5UcWxQUkEyMUx1R09oY3ZJUGVaemVWbTFyOUpkOXJ1cGNzZjNvcXY5Q3RUZlZXT1R4UlFRQUZMbVFzNzBfbHFXb0JxWExoOGkweC1LUjRjZ1RreEtvUUVDbTNoR0pKbUtXYkpocm5Xei1ONUV5WXpBVndYMl9vdE1JOXg3M0E2RFJueUtsMFU5M1UtVGdZc0U5R3c0aGd1ZFVXMDBoR0k4UjN2WnliVjg1UjhrRlZuZXlreDBiSUZ3dEwwVXlfZkxXZVBTcl9rcGNDbzZJMndpQW1rc1ZjVGs5eGVNUEhsdXIwVVJaVmxxZTNJd2M4NjhJbE9OblZGS0llbGhESFZvem1fYkZadXJ5TUx5Tl9Nc0s2dEotYms3WG9feWtKMVJmV25VSE93U1JBNEdCLWx4TlhndXgtUQ?oc=5", "source_name": "Business Wire", "published_at": "2021-11-23T08:00:00+00:00", "published_display": "23 Nov 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "NYKD: Nykode Therapeutics Doses First Patient in Abili-T Phase II Randomized Trial evaluating Abi-suva in HPV16-Positive, PD-L1-Positive Recurrent or Metastatic Head and Neck Cancer Patients", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Finansavisen", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nykode Announces Updated Strategy to Increase Value for Patients and Shareholders, Prioritizing VB10.16 as the Lead Value Driver", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwJBVV95cUxQUjZYLWduVWl1eXlmX05RR2E2SFhwaGZ0V3JaMWt6Ri1Fb3BjeGxLRG1PQzVqMy1temE4c1ZwTmw4OE8yOFR2WHhJY2xndnF3TU5rYUNsSnU5SWtjcVhveVVMRl85dXNpcmN3NXRmTkZSYWMwNlJvZ05zNVNqWkhWcXJpbXpIb1RiSjRoNWVmVWIzT3RhOGYwbmRsQmVPelZ5M2t0cmxNLXA5Z05pME5pQ3NoRjlrTG54S1FQNXdrQXZwOVR1YWh5VUd0eXFIRklvbGstMGhHY3YyZi1PX2o0U1Mya2tZLUdnWEJpVUNJdFoyVmdJbGE2c3paRWpLTWl2MjdCeEFTSnRyZXZJVnFWUkw5MVN0X042SlJMZ0ZpUFp5VUpZZEdwMUR6UQ?oc=5", "source_name": "TradingView", "published_at": "2025-08-26T07:00:00+00:00", "published_display": "26 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NYKD Stock Price and Chart \u2014 OSL:NYKD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE5ocWJDaGt2Q3VkeHpXZWlzV2Nld0Z3R19YZmF2ZjdhWFRRUGxtM25RN3dMajVSNGtyMkNmUEt0dklwT0lrTnRBTmpjMFRhS19MY2Jid2xqUms?oc=5", "source_name": "TradingView", "published_at": "2024-12-12T08:00:00+00:00", "published_display": "12 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nykode Therapeutics (Formerly Vaccibody*)) Enters Into Multi-target License and Collaboration Agreement With Regeneron to Develop Innovative Vaccines Against Cancer and Infectious Diseases", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gJBVV95cUxPTEpPVFlPaTRIcm5nejBQSXdIMXVRNW5zcDhaZWh1TG5UcWxQUkEyMUx1R09oY3ZJUGVaemVWbTFyOUpkOXJ1cGNzZjNvcXY5Q3RUZlZXT1R4UlFRQUZMbVFzNzBfbHFXb0JxWExoOGkweC1LUjRjZ1RreEtvUUVDbTNoR0pKbUtXYkpocm5Xei1ONUV5WXpBVndYMl9vdE1JOXg3M0E2RFJueUtsMFU5M1UtVGdZc0U5R3c0aGd1ZFVXMDBoR0k4UjN2WnliVjg1UjhrRlZuZXlreDBiSUZ3dEwwVXlfZkxXZVBTcl9rcGNDbzZJMndpQW1rc1ZjVGs5eGVNUEhsdXIwVVJaVmxxZTNJd2M4NjhJbE9OblZGS0llbGhESFZvem1fYkZadXJ5TUx5Tl9Nc0s2dEotYms3WG9feWtKMVJmV25VSE93U1JBNEdCLWx4TlhndXgtUQ?oc=5", "source_name": "Business Wire", "published_at": "2021-11-23T08:00:00+00:00", "published_display": "23 Nov 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 58, "total_relevant": 4, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 4, "score": 50, "total": 4, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 2.2, "count": 4}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 2.86, "latest_week": "2026-07-10", "one_week_move": -7.0, "four_week_move": -9.2, "twelve_week_move": -8.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.807051, "market_dynamics_buy_signal": false, "relative_strength": 3.327382, "fair_value_gap": -51.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 52.4267, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-7.0% over one week, -9.2% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 58, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 2}, {"label": "Finansavisen", "count": 1}, {"label": "Business Wire", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 4}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 4}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "4", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-7.0% over one week, -9.2% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "NYKD: Nykode Therapeutics Doses First Patient in Abili-T Phase II Randomized Trial evaluating Abi-suva in HPV16-Positive, PD-L1-Positive Recurrent or Metastatic Head and Neck Cancer Patients"}], "updated_at": "2026-07-16T22:50:15.036801+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}